← Back to Search

MDC Mobile App for Diabetes

Waitlist Available
Led By William Martinez, MD, MS
Research Sponsored by Vanderbilt University Medical Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Screening 3 weeks
Treatment Varies
Follow Up one month follow-up (t1)
Awards & highlights


This trial will study a new diabetes care mobile intervention to see how well it works and how users interact with it.

Who is the study for?
This trial is for adults aged 18-75 with Type 2 Diabetes who are on medication and attend Vanderbilt Medical Center or Brigham and Women's Hospital. Participants must be able to use English or Spanish, have a smartphone or tablet with internet, and an active patient web portal account.Check my eligibility
What is being tested?
The study is testing the 'My Diabetes Care' mobile app for people with Type 2 Diabetes. It aims to understand how users interact with the app, evaluate their experience, and identify any technical issues before a larger-scale trial.See study design
What are the potential side effects?
Since this trial involves using a mobile application rather than medication, traditional side effects are not applicable. However, participants may experience frustration or difficulty if they encounter usability issues with the app.


Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~one month follow-up (t1)
This trial's timeline: 3 weeks for screening, Varies for treatment, and one month follow-up (t1) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
System Usage
User Experience - Acceptance
Secondary outcome measures
Change in Diabetes Distress
Change in Diabetes Knowledge
Change in Diabetes Readiness for Change
+4 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: My Diabetes Care (MDC) MobileExperimental Treatment1 Intervention
Patients have access to a patient web portal embedded with the My Diabetes Care (MDC) intervention.

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
The most common treatments for Type 2 Diabetes include metformin, sulfonylureas, GLP-1 receptor agonists, and SGLT2 inhibitors. Metformin works by reducing glucose production in the liver and improving insulin sensitivity. Sulfonylureas increase insulin secretion from the pancreas. GLP-1 receptor agonists enhance insulin secretion, inhibit glucagon release, and slow gastric emptying. SGLT2 inhibitors reduce glucose reabsorption in the kidneys, leading to increased glucose excretion in urine. Understanding these mechanisms is crucial for patients as it helps them comprehend how their medications control blood sugar levels, which can be particularly beneficial when using a mobile app like My Diabetes Care (MDC) to track and manage their condition effectively.
A Mobile App to Improve Self-Management of Individuals With Type 2 Diabetes: Qualitative Realist Evaluation.SCORE-IT (Selecting Core Outcomes for Randomised Effectiveness trials In Type 2 diabetes): a systematic review of registered trials.

Find a Location

Who is running the clinical trial?

Vanderbilt University Medical CenterLead Sponsor
869 Previous Clinical Trials
678,557 Total Patients Enrolled
National Institutes of Health (NIH)NIH
2,736 Previous Clinical Trials
7,507,883 Total Patients Enrolled
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NIH
2,381 Previous Clinical Trials
4,315,035 Total Patients Enrolled
~26 spots leftby Jul 2025